TLIS - Talis Biomedical Corporation Stock Price, Fair Value and News

9.10USD+0.11 (+1.22%)Market Closed

Market Summary

USD9.10+0.11

Market Closed

1.22%

TLIS Stock Price

View Fullscreen

TLIS RSI Chart

TLIS Valuation

Market Cap

288.3M

Price/Earnings (Trailing)

-4.65

Price/Sales (Trailing)

135.12

Price/Free Cashflow

-5.37

TLIS Price/Sales (Trailing)

TLIS Profitability

Return on Equity

-89.71%

Return on Assets

-65.5%

Free Cashflow Yield

-18.63%

TLIS Fundamentals

TLIS Revenue

Revenue (TTM)

2.1M

Rev. Growth (Yr)

-24.12%

Rev. Growth (Qtr)

39.29%

TLIS Earnings

Earnings (TTM)

-62.0M

Earnings Growth (Yr)

50.02%

Earnings Growth (Qtr)

14.17%

Breaking Down TLIS Revenue

Last 7 days

1.1%

Last 30 days

13.8%

Last 90 days

20.7%

Trailing 12 Months

20.9%

How does TLIS drawdown profile look like?

TLIS Financial Health

Current Ratio

8.86

TLIS Investor Care

Shares Dilution (1Y)

1668.99%

Diluted EPS (TTM)

-34.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.8M	2.9M	2.2M	2.1M
2022	4.4M	4.8M	5.4M	4.8M
2021	17.5M	16.8M	7.6M	8.2M
2020	0	0	0	10.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Talis Biomedical Corporation

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 18, 2021	baker bros. advisors lp	bought	218,250	4.365	50,000	-
Aug 13, 2021	ramakrishnan ramesh	sold	-210,665	7.66	-27,502	-
Aug 13, 2021	ramakrishnan ramesh	acquired	78,532	1.5	52,355	-
May 17, 2021	scott randal w.	bought	111,210	10.11	11,000	-
May 14, 2021	scott randal w.	bought	91,440	10.16	9,000	-
Feb 17, 2021	popovits kimberly j	acquired	-	-	22,041	-
Feb 17, 2021	popovits kimberly j	bought	84,800	16.00	5,300	-
Feb 17, 2021	popovits kimberly j	acquired	-	-	209,790	-
Feb 17, 2021	scott randal w.	acquired	-	-	1,390,060	-
Feb 17, 2021	scott randal w.	bought	5,000,000	16.00	312,500	-

Which funds bought or sold TLIS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 24, 2024	BML Capital Management, LLC	unchanged	-	55,566	374,001	0.25%
Mar 11, 2024	VANGUARD GROUP INC	added	0.96	53,798	231,047	-%
Feb 14, 2024	DEUTSCHE BANK AG\	sold off	-100	-3,462	-	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	27.99	46,049	116,004	-%
Feb 14, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	unchanged	-	25,079	111,214	0.01%
Feb 14, 2024	BAKER BROS. ADVISORS LP	unchanged	-	853,982	3,787,010	0.04%
Feb 14, 2024	GREENLIGHT CAPITAL INC	unchanged	-	250,407	1,110,440	0.05%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-2,000	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	74,679	74,679	-%

Are Funds Buying or Selling TLIS?

Are funds buying TLIS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TLIS

No. of Funds

Unveiling Talis Biomedical Corporation's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	greenlight capital inc	3.9%	70,116	SC 13G/A
Mar 10, 2023	baker bros. advisors lp	66.2%	37,569,140	SC 13D/A
Feb 15, 2023	arrowmark colorado holdings llc	4.33%	1,159,016	SC 13G/A
Feb 14, 2023	greenlight capital inc	3.9%	1,051,739	SC 13G/A
Sep 12, 2022	arrowmark colorado holdings llc	4.76%	1,267,864	SC 13G/A
Jun 13, 2022	baker bros. advisors lp	66.4%	37,497,890	SC 13D/A
Feb 14, 2022	greenlight capital inc	2.8%	737,621	SC 13G
Feb 14, 2022	boxer capital, llc	0.0%	0	SC 13G/A
Feb 14, 2022	arrowmark colorado holdings llc	19.29%	5,070,446	SC 13G/A

Recent SEC filings of Talis Biomedical Corporation

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	8-K	Current Report
Mar 29, 2024	EFFECT	EFFECT
Mar 28, 2024	10-K	Annual Report
Mar 26, 2024	POS AM	POS AM
Feb 14, 2024	SC 13G/A	Major Ownership Report
Jan 26, 2024	8-K	Current Report

Peers (Alternatives to Talis Biomedical Corporation)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	184.3B	40.3B	-5.44%	-5.22%	32.76	4.57	-2.84%	-3.08%
BDX	69.5B	19.7B	-0.20%	-8.75%	52.15	3.53	4.82%	-17.56%
ALGN	21.5B	3.9B	-8.18%	-5.47%	48.35	5.57	3.42%	23.09%
BAX	18.8B	14.9B	-13.96%	-20.60%	7.1	1.26	2.98%	207.68%
MID-CAP
ATR	9.7B	3.5B	3.73%	21.66%	30.9	2.73	6.16%	35.06%
HSIC	8.8B	12.3B	-6.12%	-14.26%	21.19	0.71	-2.44%	-22.68%
BIO	8.2B	2.7B	-15.06%	-39.81%	-12.8	3.05	-4.68%	82.43%
XRAY	5.9B	3.9B	-10.84%	-29.89%	-63.02	1.5	0.23%	91.03%
AXNX	3.4B	387.1M	-2.63%	29.53%	-215.05	8.84	30.82%	65.60%
PDCO	2.3B	6.6B	-3.75%	-4.94%	11.77	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.4B	3.2B	-4.08%	-10.47%	-2.03	0.43	7.73%	-1066.14%
ANIK	409.1M	166.7M	6.81%	6.12%	-4.95	2.45	6.67%	-456.34%
ANGO	243.5M	324.0M	-1.78%	-29.87%	-1.27	0.75	-3.19%	-337.41%
APYX	49.5M	52.3M	-3.38%	-60.28%	-2.65	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-22.16%	302.94%	-0.29	0.96	5.77%	8.23%

Talis Biomedical Corporation News

Latest updates

Talis Biomedical Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	39.3%	195,000	140,000	581,000	1,218,000	257,000	796,000	572,000	3,187,000	858,000	218,000	117,000	7,000,000	233,000	9,486,000	820,000	399,000
Gross Profit	-	-	-	-	-	-	-440,000	-730,000	-334,000	-	218,000	117,000	7,000,000	-	-	-	-
Costs and Expenses	-14.4%	14,651,000	17,111,000	16,972,000	20,215,000	28,370,000	27,582,000	27,845,000	36,154,000	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	26,346,000	26,543,000	32,633,000	29,378,000	38,633,000	64,478,000	67,520,000	44,415,000	39,069,000	10,844,000	7,794,000
S&GA Expenses	-25.0%	6,602,000	8,803,000	6,410,000	6,399,000	10,796,000	8,825,000	9,178,000	11,930,000	12,316,000	12,792,000	9,983,000	7,327,000	5,305,000	3,058,000	2,660,000	2,080,000
R&D Expenses	-3.1%	8,041,000	8,302,000	10,555,000	13,796,000	15,242,000	17,521,000	17,365,000	20,703,000	17,062,000	25,841,000	54,495,000	60,193,000	39,110,000	36,011,000	8,184,000	5,714,000
Net Income	14.2%	-13,460,000	-15,682,000	-15,034,000	-17,831,000	-26,929,000	-26,021,000	-27,011,000	-33,051,000	-28,654,000	-38,418,000	-64,472,000	-60,492,000	-44,196,000	-29,514,000	-10,046,000	-7,374,000
Net Income Margin	15.5%	-29.06	-34.37	-30.09	-34.40	-23.49	-21.20	-26.29	-37.58	-23.44	-27.43	-11.80	-8.22	-8.33	-	-	-
Free Cashflow	-0.4%	-11,264,000	-11,214,000	-14,759,000	-16,489,000	-13,592,000	-21,682,000	-22,212,000	-44,265,000	-41,728,000	-75,507,000	-33,832,000	-23,183,000	-39,097,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-11.7%	95.00	107	123	133	169	194	222	231	266	303	380	403	198
Current Assets	-13.2%	78.00	90.00	102	116	133	150	174	201	236	278	354	391	189
Cash Equivalents	-12.8%	77.00	88.00	98.00	113	130	144	165	188	233	274	313	348	173
Inventory	-	-	-	-	-	-	2.00	2.00	3.00	-	-	-	-	-
Net PPE	-9.1%	3.00	3.00	4.00	4.00	3.00	7.00	10.00	11.00	11.00	10.00	10.00	10.00	9.00
Liabilities	-0.4%	26.00	26.00	27.00	23.00	43.00	42.00	45.00	28.00	32.00	44.00	86.00	-	16.00
Current Liabilities	3.8%	9.00	8.00	9.00	11.00	13.00	11.00	14.00	15.00	19.00	31.00	73.00	47.00	16.00
Shareholder's Equity	-15.3%	69.00	82.00	96.00	110	127	152	177	203	234	259	294	356	-
Retained Earnings	-2.6%	-539	-526	-510	-495	-477	-451	-425	-397	-364	-336	-297	-233	-172
Additional Paid-In Capital	0.2%	609	608	607	606	605	603	602	601	599	595	592	590	64.00
Shares Outstanding	0.2%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	-
Float	-	-	-	8,152	-	-	-	7,342	-	-	-	181,704	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-1.9%	-11,357	-11,144	-14,274	-16,465	-13,543	-20,822	-22,013	-43,758	-40,741	-74,748	-33,410	-22,485	-36,691	-32,798	-11,953	-5,582
Share Based Compensation	-4.9%	1,020	1,072	1,076	1,183	1,282	1,296	1,245	1,545	3,168	2,476	1,791	1,772	1,564	1,031	407	681
Cashflow From Investing	232.9%	93.00	-70.00	-485	-24.00	-49.00	-860	-199	-507	-987	-759	-422	-698	-2,406	-5,458	-218	-119
Cashflow From Financing	-	-	-	-	33.00	-	92.00	-	314	670	1,002	-722	233,479	122,174	13,040	111,535	5.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TLIS Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total revenue, net	$ 2,134	$ 4,812
Operating expenses:
Cost of product sold	41	8,391
Research and development	40,694	70,831
Selling, general and administrative	28,214	40,729
Total operating expenses	68,949	119,951
Loss from operations	(66,815)	(115,139)
Other income	4,808	2,127
Net loss and comprehensive loss	$ (62,007)	$ (113,012)
Net loss per share - basic	$ (34.12)	$ (62.77)
Net loss per share - diluted	$ (34.12)	$ (62.77)
Weighted average shares used in the calculation of net loss per share, basic	1,817,506	1,800,447
Weighted average shares used in the calculation of net loss per share, diluted	1,817,506	1,800,447
Grant
Revenue	$ 1,722	$ 1,160
Product revenue, net
Revenue	$ 412	$ 3,652

TLIS Balance Sheet

2023-12-31

Balance sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 76,732	$ 130,191
Accounts receivable, net	50	308
Prepaid expenses and other current assets	901	2,783
Total current assets	77,683	133,282
Property and equipment, net	3,030	3,312
Operating lease right-of-use-assets	12,419	30,920
Other long-term assets	1,542	1,776
Total assets	94,674	169,290
Current liabilities:
Accounts payable	1,339	3,768
Accrued compensation	3,836	4,212
Accrued liabilities	715	989
Operating lease liabilities, current portion	2,882	3,703
Total current liabilities	8,772	12,672
Operating lease liabilities, long-term portion	16,786	29,879
Total liabilities	25,558	42,551
Commitments and contingencies (Note 6)
Stockholders' equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized as of December 31, 2023 and December 31 2022; 1,821,986 and 1,811,396 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	0	0
Additional paid-in capital	609,074	604,690
Accumulated deficit	(539,961)	(477,954)
Total stockholders' equity	69,116	126,739
Total liabilities and stockholders equity	94,674	169,290
Series 1 Convertible Preferred Stock
Stockholders' equity:
Series 1 convertible preferred stock, $0.0001 par value-60,000,000 shares authorized as of December 31, 2023 and December 2022; 29,863,674 shares issued and outstanding as of December 31, 2023 and December 2022; aggregate liquidation preference of $3 as of December 31, 2023 and December 2022	$ 3	$ 3

About Talis Biomedical Corporation

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also develops Talis One tests for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B. The company was incorporated in 2013 and is headquartered in Redwood, California.

CEO	Mr. Robert Kelley MBA
WEBSITE	https://talisbio.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	102

Talis Biomedical Corporation Frequently Asked Questions

What is the ticker symbol for Talis Biomedical Corporation? What does TLIS stand for in stocks?

TLIS is the stock ticker symbol of Talis Biomedical Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Talis Biomedical Corporation (TLIS)?

As of Thu May 02 2024, market cap of Talis Biomedical Corporation is 288.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TLIS stock?

You can check TLIS's fair value in chart for subscribers.

What is the fair value of TLIS stock?

You can check TLIS's fair value in chart for subscribers. The fair value of Talis Biomedical Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Talis Biomedical Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TLIS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Talis Biomedical Corporation a good stock to buy?

The fair value guage provides a quick view whether TLIS is over valued or under valued. Whether Talis Biomedical Corporation is cheap or expensive depends on the assumptions which impact Talis Biomedical Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TLIS.

What is Talis Biomedical Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, TLIS's PE ratio (Price to Earnings) is -4.65 and Price to Sales (PS) ratio is 135.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TLIS PE ratio will change depending on the future growth rate expectations of investors.